GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cancer Prevention Pharmaceuticals Inc (AMEX:CPP) » Definitions » Tariff Resilience Score

CPP (Cancer Prevention Pharmaceuticals) Tariff Resilience Score : 0/10 (As of Jun. 23, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Cancer Prevention Pharmaceuticals Tariff Resilience Score?

Cancer Prevention Pharmaceuticals has the Tariff Resilience Score of 0, which implies that the company might have .

Cancer Prevention Pharmaceuticals has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Cancer Prevention Pharmaceuticals might have .

Cancer Prevention Pharmaceuticals  (AMEX:CPP) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Cancer Prevention Pharmaceuticals Tariff Resilience Score Related Terms

Thank you for viewing the detailed overview of Cancer Prevention Pharmaceuticals's Tariff Resilience Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Cancer Prevention Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cancer Prevention Pharmaceuticals Inc (AMEX:CPP) » Definitions » Tariff Resilience Score
Comparable Companies
NUVPF ADMD RSPI YBAO ULUR NRXCF ACUR LBLTF PUFXF BKIT RLMD IGC MYOS CBICF SBFM PVCT AQSZF PTLF AOLS APRI
Traded in Other Exchanges
N/A
Address
Website
http://www.canprevent.com
Cancer Prevention Pharmaceuticals Inc is a pharmaceutical company. It was originally incorporated under the laws of the state of Arizona on June 9, 2008, as Cancer Prevention Pharmaceuticals, LLC and on December 22, 2009, Cancer Prevention Pharmaceuticals, Inc. was incorporated in the state of Delaware. The Company currently operates mainly in the development and commercialization of compound CPP-1X, otherwise known as DFMO or eflornithine. It is involved in familial adenomatous polyposis, neuroblastoma and the prevention of recurrence in colon cancer survivors. However, CPP also has therapeutic prevention approaches for prostate cancer, breast cancer, and skin cancers which will be developed together with the National Cancer Institute (as resources become available in the future) and multiple academic partners. Its competitors are Marina Biotech, Inc., SLA Pharma AG, StemSynergy Therapeutics, Inc. and Thetis Pharmaceuticals LLC. The Company holds license to approximately six issued patents in the United States. The Company's activities are subject to risks and uncertainties including failure to obtain required regulatory approvals to market the products, once developed, in the USA or foreign markets.

Cancer Prevention Pharmaceuticals Headlines